Cargando…

Serum p53 antibody detection in patients with impaired lung function

BACKGROUND: TP53 gene mutations can lead to the expression of a dysfunctional protein that in turn may enable genetically unstable cells to survive and change into malignant cells. Mutant p53 accumulates early in cells and can precociously induce circulating anti-p53 antibodies (p53Abs); in fact, p5...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattioni, Manlio, Chinzari, Patrizia, Soddu, Silvia, Strigari, Lidia, Cilenti, Vincenzo, Mastropasqua, Eliuccia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570357/
https://www.ncbi.nlm.nih.gov/pubmed/23384026
http://dx.doi.org/10.1186/1471-2407-13-62
_version_ 1782259055528509440
author Mattioni, Manlio
Chinzari, Patrizia
Soddu, Silvia
Strigari, Lidia
Cilenti, Vincenzo
Mastropasqua, Eliuccia
author_facet Mattioni, Manlio
Chinzari, Patrizia
Soddu, Silvia
Strigari, Lidia
Cilenti, Vincenzo
Mastropasqua, Eliuccia
author_sort Mattioni, Manlio
collection PubMed
description BACKGROUND: TP53 gene mutations can lead to the expression of a dysfunctional protein that in turn may enable genetically unstable cells to survive and change into malignant cells. Mutant p53 accumulates early in cells and can precociously induce circulating anti-p53 antibodies (p53Abs); in fact, p53 overexpression has been observed in pre-neoplastic lesions, such as bronchial dysplasia, and p53Abs have been found in patients with Chronic Obstructive Pulmonary Disease, before the diagnosis of lung and other tobacco-related tumors. METHODS: A large prospective study was carried out, enrolling non-smokers, ex-smokers and smokers with or without the impairment of lung function, to analyze the incidence of serum p53Abs and the correlation with clinicopathologic features, in particular smoking habits and impairment of lung function, in order to investigate their possible role as early markers of the onset of lung cancer or other cancers. The p53Ab levels were evaluated by a specific ELISA in 675 subjects. RESULTS: Data showed that significant levels of serum p53Abs were present in 35 subjects (5.2%); no difference was observed in the presence of p53Abs with regard to age and gender, while p53Abs correlated with the number of cigarettes smoked per day and packs-year. Furthermore, serum p53Abs were associated with the worst lung function impairment. The median p53Ab level in positive subjects was 3.5 units/ml (range 1.2 to 65.3 units/ml). Only fifteen positive subjects participated in the follow-up, again resulting positive for serum p53Abs, and no evidence of cancer was found in these patients. CONCLUSION: The presence of serum p53Abs was found to be associated with smoking level and lung function impairment, both risk factors of cancer development. However, in our study we have not observed the occurrence of lung cancer or other cancers in the follow-up of positive subjects, therefore we cannot directly correlate the presence of serum p53Abs with cancer risk.
format Online
Article
Text
id pubmed-3570357
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35703572013-02-13 Serum p53 antibody detection in patients with impaired lung function Mattioni, Manlio Chinzari, Patrizia Soddu, Silvia Strigari, Lidia Cilenti, Vincenzo Mastropasqua, Eliuccia BMC Cancer Research Article BACKGROUND: TP53 gene mutations can lead to the expression of a dysfunctional protein that in turn may enable genetically unstable cells to survive and change into malignant cells. Mutant p53 accumulates early in cells and can precociously induce circulating anti-p53 antibodies (p53Abs); in fact, p53 overexpression has been observed in pre-neoplastic lesions, such as bronchial dysplasia, and p53Abs have been found in patients with Chronic Obstructive Pulmonary Disease, before the diagnosis of lung and other tobacco-related tumors. METHODS: A large prospective study was carried out, enrolling non-smokers, ex-smokers and smokers with or without the impairment of lung function, to analyze the incidence of serum p53Abs and the correlation with clinicopathologic features, in particular smoking habits and impairment of lung function, in order to investigate their possible role as early markers of the onset of lung cancer or other cancers. The p53Ab levels were evaluated by a specific ELISA in 675 subjects. RESULTS: Data showed that significant levels of serum p53Abs were present in 35 subjects (5.2%); no difference was observed in the presence of p53Abs with regard to age and gender, while p53Abs correlated with the number of cigarettes smoked per day and packs-year. Furthermore, serum p53Abs were associated with the worst lung function impairment. The median p53Ab level in positive subjects was 3.5 units/ml (range 1.2 to 65.3 units/ml). Only fifteen positive subjects participated in the follow-up, again resulting positive for serum p53Abs, and no evidence of cancer was found in these patients. CONCLUSION: The presence of serum p53Abs was found to be associated with smoking level and lung function impairment, both risk factors of cancer development. However, in our study we have not observed the occurrence of lung cancer or other cancers in the follow-up of positive subjects, therefore we cannot directly correlate the presence of serum p53Abs with cancer risk. BioMed Central 2013-02-06 /pmc/articles/PMC3570357/ /pubmed/23384026 http://dx.doi.org/10.1186/1471-2407-13-62 Text en Copyright ©2013 Mattioni et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mattioni, Manlio
Chinzari, Patrizia
Soddu, Silvia
Strigari, Lidia
Cilenti, Vincenzo
Mastropasqua, Eliuccia
Serum p53 antibody detection in patients with impaired lung function
title Serum p53 antibody detection in patients with impaired lung function
title_full Serum p53 antibody detection in patients with impaired lung function
title_fullStr Serum p53 antibody detection in patients with impaired lung function
title_full_unstemmed Serum p53 antibody detection in patients with impaired lung function
title_short Serum p53 antibody detection in patients with impaired lung function
title_sort serum p53 antibody detection in patients with impaired lung function
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570357/
https://www.ncbi.nlm.nih.gov/pubmed/23384026
http://dx.doi.org/10.1186/1471-2407-13-62
work_keys_str_mv AT mattionimanlio serump53antibodydetectioninpatientswithimpairedlungfunction
AT chinzaripatrizia serump53antibodydetectioninpatientswithimpairedlungfunction
AT soddusilvia serump53antibodydetectioninpatientswithimpairedlungfunction
AT strigarilidia serump53antibodydetectioninpatientswithimpairedlungfunction
AT cilentivincenzo serump53antibodydetectioninpatientswithimpairedlungfunction
AT mastropasquaeliuccia serump53antibodydetectioninpatientswithimpairedlungfunction